Answers are grounded in this paper and cite their sources.
This expert consensus provides tailored recommendations for the selection and dosing of oral anticoagulants in Korean patients with atrial fibrillation, addressing specific high-risk clinical scenarios where international guidelines may have limited application.
Oral anticoagulants (OAC) are necessary to prevent thromboembolism in patients with atrial fibrillation (AF). OACs used in Korea are composed of warfarin and non-vitamin K antagonist OAC. Risk stratification and selection of OACs in patients with AF is usually performed by international guidelines for AF management. However, these guidelines do not always reflect the unique characteristics of AF patients in Korea as they were established based on a small portion of the Asian population and, therefore, have limited application to Korean patients. In addition, under certain conditions, the choice of OACs and doses according to the international guidelines are unsuitable for Korean AF patients. Recently, robust clinical data of Korean AF patients have become
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a review in Atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin was evaluated. The 2018 KHRS Expert Consensus provides specific recommendations for the selection and dosing of non-vitamin K antagonist oral anticoagulants compared to warfarin in Korean patients with atrial fibrillation across various high-risk clinical scenarios.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: